Esperion Therapeutics, a Plythmouth, Michigan-based company that discovers and develops novel therapies for the treatment of cardiovascular and metabolic diseases, has appointed Noah Rosenberg, MD, as its chief medical officer.
Rosenberg will lead the Esperion clinical advisory board and will develop and manage the company's clinical programs. He will also manage the regulatory review process for the company's investigational therapies to prevent, treat and reverse cardiovascular and metabolic diseases. In addition, Rosenberg will play an instrumental role in corporate planning related to financing to support the ongoing development of Esperion's novel portfolio.
Rosenberg has held several senior posts in the pharmaceutical industry, including leadership roles in medical affairs, clinical development and administration in the U.S. and globally at Pfizer, Sanofi-Aventis and Forest Laboratories. He has experience working on compounds in all phases of drug development including late stage drugs such as Lipitor and Lantus. Most recently at Forest Research Institute (FRI), he led the successful in-licensing of the GK1-399 program and, until his departure, served as a standing member of the Joint Development Committee (JDC) with partner TransTech Pharma. Noah also coordinated the successful integration of the Forest cardiovascular and metabolism clinical development teams and managed the group through a highly productive period, helping to strengthen a pipeline that ultimately included compounds such as bystolic and azimilide.